Clinical trials: Irritable Bowel Syndrome - Constipation
Irritable Bowel Syndrome Characterized by Constipation
Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.
- Trial name
- IBS-C (NCT02493452)
- Testing
- Plecanatide
- Where
- 191 sites in United States
- Volunteers
- 1,135 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Constipation (CC) (Excluding Constipation Due to Organic Diseases), Irritable Bowel Syndrome With Constipation (IBS-C)
Post-marketing Surveillance of Linaclotide Tablet in Patients With Irritable Bowel Syndrome With Constipation or Chronic Constipation (Excluding Constipation Due to Organic Diseases)
The objective of this study is to evaluate the long-term safety and efficacy of linaclotide in post-marketing use.
- Trial name
- NCT03471728
- Testing
- linaclotide
- Where
- 47 sites in Japan
- Volunteers
- 2,475 people
- Sponsor
- Astellas Pharma Inc
Functional Dyspepsia, Constipation-predominant Irritable Bowel Syndrome
Efficacy of Linaclotide in Patients With Overlapping Functional Gastrointestinal Disorders
This study aims to assess the efficacy and safety of linaclotide in patients with overlapping symptoms of both functional dyspepsia (FD) and constipation-predominant irritable bowel syndrome (IBS-C).
- Trial name
- NCT05134584
- Testing
- Linaclotide, Lactulose, Omeprazol
- Where
- China
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- RenJi Hospital
Irritable Bowel Syndrome
Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome
The general aim of the current study is to describe the effect of pregabalin on colonic and sensory functions in adults with constipation predominant irritable bowel syndrome (IBS-C). Study hypotheses: 1.
- Trial name
- NCT01331213
- Testing
- Pregabalin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant)
Saccharomyces Boulardii CNCM I-745 in Irritable Bowel Syndrome
This is a double-blind, randomized (group assignment by chance), placebo-controlled, multicenter trial which will be conducted over a 13.5-months period The main objective of the research is to demonstrate the efficacy of…
- Conditions
- IBS (Irritable Bowel Syndrome), IBS-D (Diarrhea-predominant), IBS, Mixed Symptoms
- Trial name
- BoWell Sb252 (NCT07168434)
- Testing
- Saccharomyces Boulardii 250 MG
- Where
- 10 sites in Portugal, Spain
- Volunteers
- 406 people
- Sponsor
- Biocodex
Irritable Bowel Syndrome Characterized by Constipation
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
To evaluate the efficacy on abdominal symptoms (abdominal bloating, abdominal discomfort, and abdominal pain) and safety of linaclotide 290 μg administered orally to patients with IBS-C.
- Trial name
- NCT03573908
- Testing
- Linaclotide
- Where
- 79 sites in United States
- Volunteers
- 614 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome
Fecal Microbiota Transplantation to Relieve Symptoms of Irritable Bowel Syndrome Without Constipation
Irritable bowel syndrome (IBS) is a complex multifactorial functional disorder, whose pathophysiology is largely associated to an impairment of the intestinal microbiota composition, namely dysbiosis.
- Trial name
- TRAMIR (NCT05803980)
- Testing
- Fecal microbiota transplantation (FMT)
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Irritable Bowel Syndrome
A Study of the Safety and Effectiveness of DDP733 in Treating IBS With Constipation in Females
This study will evaluate the safety and effectiveness of the investigational drug DDP733 in treating female patients with IBS-c. A placebo control will be utilized.
- Trial name
- NCT00547469
- Testing
- DDP733
- Where
- 69 sites in United States, Canada
- Volunteers
- 360 people
- Sponsor
- Dynogen Pharmaceuticals
Non-Constipation Irritable Bowel Syndrome
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
- Trial name
- TARGET 2 (NCT00724126)
- Testing
- Rifaximin
- Where
- 88 sites in United States
- Volunteers
- 637 people
- Sponsor
- Bausch Health Americas, Inc.
Constipation Predominant Irritable Bowel Syndrome
The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
This phase 2, randomized, double blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of three dose levels of AZD1722 in subjects with constipation predominant IBS (IBS-C) as defined by the ROME III…
- Trial name
- NCT01923428
- Testing
- AZD1722
- Where
- 4 sites in United States
- Volunteers
- 356 people
- Sponsor
- Ardelyx
Irritable Bowel Syndrome With Constipation
Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C.
- Trial name
- NCT00460811
- Testing
- Linaclotide Acetate
- Where
- 85 sites in United States, Canada
- Volunteers
- 420 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome
Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome
In patients with IBS, will supplementation with a probiotic demonstrate symptomatic efficacy and will the probiotic influence gut microflora and thus improve clinical outcomes, as compared to no intervention.
- Trial name
- NCT01886781
- Testing
- Lactobacillus plantarum 299v, Run in period, Wash - out period
- Where
- South Africa
- Volunteers
- 81 people
- Sponsor
- University of Stellenbosch
Irritable Bowel Syndrome (IBS-C)
Trans Auricular Vagal Nerve Stimulation in Patients With IBS-C
This study evaluates the efficacy and safety of transcutaneous auricular vagus nerve stimulation (ta-VNS) in adults with constipation-predominant irritable bowel syndrome (IBS-C).
- Trial name
- NCT07662083
- Testing
- Transcutaneous Auricular Vagus Nerve Stimulation (ta-VNS)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- West Virginia University
Irritable Bowel Syndrome Characterized by Constipation
The Plecanatide Irritable Bowel Syndrome With Constipation Safety and Efficacy Study (IBS-C)
This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.
- Trial name
- IBS-C (NCT02387359)
- Testing
- Plecanatide
- Where
- 155 sites in United States
- Volunteers
- 1,054 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome With Constipation (IBS-C)
A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C
A Single-Dose, Open-Label, Extension Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients with Irritable Bowel Syndrome with Constipation
- Trial name
- NCT02493036
- Testing
- SYN-010
- Where
- 11 sites in United States
- Volunteers
- 54 people
- Sponsor
- Theriva Biologics, Inc.
Irritable Bowel Syndrome With Constipation
An Evaluation of Cultured Milk Drink on Immune Status of Patients With Irritable Bowel Syndrome: Constipation Predominant
Our previous work on the use of probiotics improved the clinical symptoms in irritable bowel syndrome with constipation-predominant.
- Trial name
- NCT04647045
- Testing
- Cultured milk drink
- Where
- Malaysia
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- National University of Malaysia
Irritable Bowel Syndrome With Constipation
Efficacy and Safety of SYN-010 in IBS-C
Irritable bowel syndrome (IBS) is a gastrointestinal (GI) syndrome characterized by chronic abdominal pain and altered bowel habits in the absence of any organic cause.
- Trial name
- NCT03763175
- Testing
- SYN-010 21 mg, SYN-010 42 mg
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- Cedars-Sinai Medical Center
Irritable Bowel Syndrome, Digestive System Diseases
Efficacy of a Multi-strain Probiotic in the Treatment of Irritable Bowel Syndrome
The Canadian College of Naturopathic Medicine is conducting a research study on Irritable Bowel Syndrome (IBS), a common condition in North America.
- Conditions
- Irritable Bowel Syndrome, Digestive System Diseases, Colonic Diseases, Functional, Colitis, Mucous
- Trial name
- IBS (NCT01887834)
- Testing
- Kyodophilus multi-strain probiotic capsules
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- The Canadian College of Naturopathic Medicine
Irritable Bowel Syndrome Characterized by Constipation
Botanical Tincture for Symptoms of Irritable Bowel Syndrome
The main purpose of this study is to investigate the feasibility of a follow-up larger RCT on the efficacy of Botanical Tincture to relieve abdominal pain in people with Irritable Bowel Syndrome Constipation Predominant (IBS-C).
- Trial name
- NCT03923322
- Testing
- Botanical Tincture
- Where
- United States
- Sponsor
- Stamford Hospital
Constipation-predominant IBS (IBS-C)
Use of Novel Prebiotic Fiber for Targeted Dietary Management of Irritable Bowel Syndrome (Nutrabiotix Phase II)
The objective of this Phase II trial is to test the NTX-1 Fiber in patients with constipation-predominant IBS (IBS-C) and determine if it can reduce symptoms, beneficially modify gut microbiota composition, and improve gut milieu…
- Trial name
- NCT02144753
- Testing
- NTX-1, psyllium (15 g)
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Nutrabiotix, LLC